Investigators have developed and validated 2 new fracture risk algorithms for estimating the individual risk of osteoporotic fracture or hip fracture over a 10-year time period.
Investigators have developed and validated 2 new fracture risk algorithms for estimating the individual risk of osteoporotic fracture or hip fracture over a 10-year time period. Researchers used data from more than 2 million male and female patients between the ages of 30 and 85 years from 574 general practices in England and Wales, gleaned over a 15-year period. Two-thirds of practices were allocated to the derivation dataset and the remaining third to the validation dataset (practices from which data were not used to develop the algorithms).
According to the study, reported in the British Medical Journal, osteoporotic fracture risk in women was significantly and independently associated with use of hormone replacement therapy, age, smoking status, alcohol use, parental history of osteoporosis, rheumatoid arthritis, cardiovascular disease, type 2 diabetes, asthma, use of tricyclic antidepressants or corticosteroids, history of falls, menopausal symptoms, chronic liver disease, gastrointestinal malabsorption, and other endocrine disorders. However, not all of these variables were associated with risk of hip fracture.
Because the algorithms can predict fracture risk without laboratory measurements, they are suitable in both clinical settings and for self-assessment. A questionnaire and calculator of 10-year risk for osteoporotic fracture or hip fracture based on the algorithms are available at http://www.qfracture.org/.
Increase in ED visits for hypertensive disorders from 2006 to 2020 reported
September 18th 2024In a recent study, reported rates on emergency department utilization for hypertensive disorders of pregnancy and the postpartum period were higher in 2020 than 2006, with rates especially high among non-Hispanic Black, Hispanic, and Asian patients.
Read More
SKYLIGHT trials confirm safety and efficacy of fezolinetant against sleep disturbances
September 13th 2024At the 2024 Annual Meeting of The Menopause Society, the positive safety and efficacy data of fezolinetant against sleep disturbances from the SKYLIGHT 1 and 2 trials was presented.
Read More